Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET

Company Participants

Matthew Murphy - Manager, Investor Relations

Christopher Posner - President, CEO & Director

Ryan Maynard - CFO

Joana Goncalves - Chief Medical Officer

Conference Call Participants

Sumant Kulkarni - Canaccord Genuity

Joseph Stringer - Needham & Company

Daniel Wolle - JPMorgan Chase & Co.

Chi Meng Fong - Bank of America Merrill Lynch

Stacy Lee - Stifel

David Amsellem - Piper Sandler & Co.

Operator

Good afternoon. My name is Shannon, and I will be your conference facilitator. I would like to welcome everyone to the Cara Therapeutics Third Quarter 2022 Financial Results and Update Conference Call. [Operator Instructions].

I would now like to introduce Matt Murphy, Cara's Manager of Investor Relations. Mr. Murphy, you may begin your call.

Matthew Murphy

Thank you, operator, and good afternoon. Just after market close today, Cara issued a news release announcing the company's results for the third quarter of 2022. Copies of this news release and SEC filings can be found in the Investors section of our website at www.caratherapeutics.com.

Before we begin, I would like to remind you that during the course of this conference call we will be making certain forward-looking statements about Cara and our programs based on management's current plans and expectations. These statements are being made under the Private Securities Litigation Reform Act of 1995, and they are subject to various risks and uncertainties. Actual results may differ materially due to various factors, and Cara is under no duty to update these statements publicly. Investors should read the risk factors set forth in Cara's 10-K for the year ended December 31, 2021, and the 10-Q for the quarter ended September 30, 2022, and any subsequent reports filed with the SEC.

With that said, I'd like to turn the call over to Chris Posner, Cara's Chief Executive Officer. Chris?

Christopher Posner

Thanks, Matt, and good afternoon, everyone. The third quarter was about traction for Cara, where strong execution on our strategy has started to propel us on the road to accelerated growth for years to come. We believe our goal to become the world leader in pruritus has a unique long-term value proposition. Our clear focus is to provide potential solutions to this underserved condition affecting millions across many disease areas. As we gain strategic momentum, this focus is a differentiating factor.